Immuron reports Phase II data for NASH candidate

Immuron Ltd. (ASX:IMC; NASDAQ:IMRN) reported top-line data from a Phase II trial in 133 patients with non-alcoholic steatohepatitis (NASH) showing that

Read the full 211 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE